Top 10 Generic Pharma Manufacturing Companies in Vietnam (2026 Update)

Vietnam’s pharmaceutical industry is experiencing unprecedented growth. Driven by a rapidly aging population, increasing government healthcare expenditure, and a strong national push to reduce reliance on imported medicines, the domestic generic drug market is booming.

As we move through 2026, the landscape of pharma manufacturing in Vietnam is shifting. The most significant trend? A massive transition from basic WHO-GMP compliance to the rigorous EU-GMP and PIC/S standards. This shift allows Vietnamese manufacturers to not only dominate the local hospital bidding channels but also export their generic drugs to global markets.

Whether you are a B2B distributor, an investor, or a pharmaceutical equipment supplier, understanding the key players is crucial. Based on production capacity, market share, and technological advancement, here are the Top 10 Generic Pharma Manufacturing Companies in Vietnam for 2026.

DHG Pharmaceutical Joint-Stock Company (DHG Pharma)

As the undisputed leader in Vietnam’s pharmaceutical sector, DHG Pharma boasts the largest market share in domestic generic drugs. Backed by Japan’s Taisho Pharmaceutical, DHG has successfully upgraded several of its production lines to Japan-GMP standards, focusing heavily on analgesics, antibiotics, and cardiovascular generics.

Imexpharm Corporation

Imexpharm is the pioneer of high-quality antibiotics in Vietnam. They were among the first domestic companies to invest heavily in EU-GMP standard factories. Their unwavering commitment to European manufacturing standards has made them the top choice for premium generic medicines in Vietnam’s tier-1 hospitals.

Traphaco JSC

While traditionally famous for herbal and traditional medicines, Traphaco has aggressively expanded into the modern generic drug space. With their new, highly automated smart factories, they have scaled up the production of OTC and prescription generics, setting a benchmark for modern pharma manufacturing in Northern Vietnam.

Pymepharco

Fully acquired by the global generic giant STADA, Pymepharco is a manufacturing powerhouse. Operating multiple state-of-the-art EU-GMP certified plants in Phu Yen, they produce a vast portfolio of high-quality generics that supply both the domestic market and STADA’s global supply chain.

Domesco Medical Import-Export JSC

With major backing from Abbott, Domesco has solidified its position in the generic prescription drug market. They specialize in treatments for chronic diseases, particularly cardiovascular and endocrine system disorders, utilizing advanced formulation and tableting technologies.

RV OPV Pharmaceuticals

With a rich history dating back to 1950, OPV Pharmaceutical is a prominent manufacturer of both prescription and OTC healthcare products. Recently acquired by RV Group, OPV is aggressively upgrading its manufacturing capabilities to improve access to affordable, high-quality medicines across Indochina.

Bidiphar (Binh Dinh Pharmaceutical and Medical Equipment JSC)

Bidiphar stands out for its specialized manufacturing capabilities. They are the leading domestic producer of generic oncology drugs (cancer treatments) and sterile injectables. Handling such highly potent active pharmaceutical ingredients (APIs) requires world-class isolation and mixing equipment.

Ha Tay Pharmaceutical JSC (Hataphar)

Partnered with Japan’s ASKA Pharmaceutical, Hataphar is rapidly expanding its production capacity. They are currently building new high-tech manufacturing facilities designed to meet Japan-GMP and EU-GMP standards, focusing on high-volume generic solid dosages.

Nanogen Pharmaceutical Biotechnology JSC

While primarily known for its pioneering work in biologics and vaccines, Nanogen is a crucial player in the broader therapeutic solutions market. Their highly advanced R&D and manufacturing capabilities for APIs and biosimilars represent the cutting edge of Vietnam’s life science sector.

Innocare Pharmaceuticals Co., Ltd.

A rising star in the Vietnamese market, Innocare focuses heavily on innovative R&D and specialized generic formulations. They have carved out a strong niche in dermatological treatments and advanced spray formulations, proving that Vietnamese manufacturers are moving beyond basic pills and capsules.

The Secret Behind Their Success: World-Class Manufacturing Equipment

What do industry giants like Imexpharm, DHG, and Pymepharco have in common? They do not compromise on their manufacturing equipment.

To pass strict EU-GMP audits and secure lucrative government hospital contracts, Vietnamese pharmaceutical companies are rapidly replacing outdated machinery with premium, highly automated equipment. Consistent drug efficacy relies entirely on the precision of the manufacturing process.

At Jianpai Technology, we supply the world-class pharmaceutical machinery that powers top-tier generic manufacturing globally:

• Granulation & Drying: Achieving perfect moisture content is critical for generic APIs. Our Fluid Bed Dryers ensure uniform heat distribution and rapid drying without degrading sensitive compounds.

• Homogeneous Blending: For highly potent generics, absolute uniformity is required. Our High Shear Mixers (equipped with premium global components like Siemens and Festo) guarantee zero dead zones.

• Precision Coating: For sustained-release generic tablets, our automated Tablet Coating machines deliver surgical precision, ensuring exact film thickness batch after batch.

• The Future of Pharma: As Vietnam looks toward the next decade, forward-thinking companies are exploring Continuous Manufacturing lines to drastically reduce operational costs and increase output.

Upgrade Your Production Line for EU-GMP Compliance

If you are a pharmaceutical manufacturer in Vietnam or Southeast Asia looking to upgrade your facility to EU-GMP or PIC/S standards, reliable equipment is your first step.

[Contact Jianpai Technology today] to consult with our engineering experts. Let us help you design, install, and validate the pharmaceutical machinery that will drive your success in 2026 and beyond.